Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of “Buy” by Brokerages

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has been assigned an average recommendation of “Buy” from the ten analysts that are currently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $18.63.

A number of research firms have commented on TRVI. Oppenheimer upped their price target on Trevi Therapeutics from $12.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Raymond James raised Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price objective for the stock from $9.00 to $29.00 in a research report on Monday, March 10th. D. Boral Capital reaffirmed a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research report on Monday. B. Riley reaffirmed a “buy” rating and set a $20.00 price objective (up previously from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $24.00 price objective on shares of Trevi Therapeutics in a research report on Tuesday, May 20th.

Insider Activity at Trevi Therapeutics

In other Trevi Therapeutics news, CEO Jennifer L. Good sold 5,263 shares of the firm’s stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $6.58, for a total transaction of $34,630.54. Following the transaction, the chief executive officer now owns 213,313 shares of the company’s stock, valued at approximately $1,403,599.54. This trade represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Farrell Simon sold 81,313 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the transaction, the insider now directly owns 76,900 shares in the company, valued at approximately $519,075. The trade was a 51.39% decrease in their position. The disclosure for this sale can be found here. 18.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Trevi Therapeutics

Hedge funds have recently made changes to their positions in the company. Summit Investment Advisors Inc. grew its holdings in shares of Trevi Therapeutics by 84.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock worth $26,000 after purchasing an additional 2,894 shares during the last quarter. Strs Ohio acquired a new stake in shares of Trevi Therapeutics during the first quarter worth about $52,000. Raymond James Financial Inc. acquired a new stake in shares of Trevi Therapeutics during the fourth quarter worth about $49,000. Squarepoint Ops LLC acquired a new stake in shares of Trevi Therapeutics during the fourth quarter worth about $58,000. Finally, Diversified Trust Co acquired a new stake in shares of Trevi Therapeutics during the first quarter worth about $94,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Stock Performance

TRVI opened at $6.74 on Friday. The business’s 50 day moving average price is $6.24 and its 200 day moving average price is $4.96. Trevi Therapeutics has a one year low of $2.30 and a one year high of $7.48. The stock has a market capitalization of $673.28 million, a PE ratio of -15.32 and a beta of 0.59.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.04. As a group, equities research analysts forecast that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.